Developer docs
API playgroundTry for free, no card

Search company profiles

VG Life Sciences

Full company profile

uuid003l7ag

Namestring
VG Life Sciences
Company typeenum
Private
Founded yearint
1995
Descriptiontext

VG Life Sciences is, on the basis of available source material, effectively a shell entity with no observable commercial operations. Its only digital footprint, the domain vglifesciences.com, resolves to a default WordPress installation branded "Praise The Sun" — a generic theme site containing just two placeholder posts ("Second" and "Hi") dated August 20, 2024, with body text consisting only of the words "Second" and "First." There is no indication of products, services, technology stack, scientific platform, clinical pipeline, or therapeutic focus that would be expected of a life sciences company.

The structured input confirms this: products_and_services is empty, headcount is empty, revenue is null with no currency or value, company_type cannot be determined, founded_year is blank, and ownership_commentary records no investors, parent, or founder disclosure. The site's sole author identifier is "admin," and the most recent post dates to August 2024 with no subsequent activity. No management team, partnerships, certifications, regulatory actions, M&A activity, funding rounds, or geographic operations are recorded.

Given the absence of any substantive operational, financial, scientific, or organizational data, the company cannot be described as having an active business model, identifiable customers, or a go-to-market motion. The available evidence supports only the characterization that VG Life Sciences is an entity whose public-facing presence is dormant or undeveloped as of the source capture date, and any inference of life sciences activity (drug development, diagnostics, biologics, etc.) would be unsupported by the input.

Short descriptiontext

VG Life Sciences is a company whose only documented presence is a placeholder WordPress website titled "Praise The Sun," with no disclosed products, services, customers, leadership, funding, or operational activity in the source data.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSouth Pasadena, United States
HQ citystring
South Pasadena
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
life sciences research, biotechnology development, pharmaceutical sciences, biomedical research, therapeutic discovery
Product category
Life Sciences
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

The source data contains no substantive information about VG Life Sciences' products or services. The company's website (vglifesciences.com) is a placeholder WordPress installation branded as 'Praise The Sun' that contains only sample posts titled 'Second' and 'Hi' from August 2024, with no descriptions of actual offerings.

Differentiator
Functional benefit
Problem solved
Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Market position
Weaknesses2 records

Each record includes

Headline, Details, Source

Competitive moat1 record

Each record includes

Type, Details

Key risks2 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

VG Life Sciences

Life Sciencesvglifesciences.com

VG Life Sciences is a company whose only documented presence is a placeholder WordPress website titled "Praise The Sun," with no disclosed products, services, customers, leadership, funding, or operational activity in the source data.

What VG Life Sciences does

VG Life Sciences is, on the basis of available source material, effectively a shell entity with no observable commercial operations. Its only digital footprint, the domain vglifesciences.com, resolves to a default WordPress installation branded "Praise The Sun" — a generic theme site containing just two placeholder posts ("Second" and "Hi") dated August 20, 2024, with body text consisting only of the words "Second" and "First." There is no indication of products, services, technology stack, scientific platform, clinical pipeline, or therapeutic focus that would be expected of a life sciences company.

The structured input confirms this: products_and_services is empty, headcount is empty, revenue is null with no currency or value, company_type cannot be determined, founded_year is blank, and ownership_commentary records no investors, parent, or founder disclosure. The site's sole author identifier is "admin," and the most recent post dates to August 2024 with no subsequent activity. No management team, partnerships, certifications, regulatory actions, M&A activity, funding rounds, or geographic operations are recorded.

Given the absence of any substantive operational, financial, scientific, or organizational data, the company cannot be described as having an active business model, identifiable customers, or a go-to-market motion. The available evidence supports only the characterization that VG Life Sciences is an entity whose public-facing presence is dormant or undeveloped as of the source capture date, and any inference of life sciences activity (drug development, diagnostics, biologics, etc.) would be unsupported by the input.

VG Life Sciences firmographics

Firmographics
Name
VG Life Sciences
Website
https://vglifesciences.com
Company type
Private
Founded year
1995
Operating status
Operating
Headcount range
11–50 employees
Short description
VG Life Sciences is a company whose only documented presence is a placeholder WordPress website titled "Praise The Sun," with no disclosed products, services, customers, leadership, funding, or operational activity in the source data.
Ownership category
akta.pro rank

Where VG Life Sciences is headquartered

Location

Headquarters

HQ city
South Pasadena
HQ country
United States
HQ region
North America

Markets served

VG Life Sciences business model

Business model
GTM type
B2B
Offering type
Services

VG Life Sciences product offering

Product offering

Core offering

The source data contains no substantive information about VG Life Sciences' products or services. The company's website (vglifesciences.com) is a placeholder WordPress installation branded as 'Praise The Sun' that contains only sample posts titled 'Second' and 'Hi' from August 2024, with no descriptions of actual offerings.

Differentiator

Problem solved

Functional benefit

Companies that use VG Life Sciences

Customer profile

Ideal customer profiles1 record

VG Life Sciences technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

VG Life Sciences partnerships and signals

Strategic signal

Recent moves2 records

VG Life Sciences competitors and assessment

Company assessment

Market position

Weaknesses2 records

Competitive moat1 record

Key risks2 records

Customer concentration

VG Life Sciences social profiles

Digital presence

VG Life Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

VG Life Sciences leadership team

Management profile

Number of profiles

VG Life Sciences funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

VG Life Sciences M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VG Life Sciences

What does VG Life Sciences do?

The source data contains no substantive information about VG Life Sciences' products or services. The company's website (vglifesciences.com) is a placeholder WordPress installation branded as 'Praise The Sun' that contains only sample posts titled 'Second' and 'Hi' from August 2024, with no descriptions of actual offerings.

When was VG Life Sciences founded?

VG Life Sciences was founded in 1995. It employs 11 to 50 people.

Where is VG Life Sciences based?

VG Life Sciences is headquartered in South Pasadena, United States, in the North America region.

Does VG Life Sciences have an API?

No public API is recorded for VG Life Sciences.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireVG Life Sciences Announces Issuance of Patent Covering Treatment of Inflammatory Bowel Disease with Clip-Inducing AgentVG Life Sciences announced the USPTO issued U.S. Patent No. 8906846 covering a method to treat inflammatory bowel disease with a CLIP-inducing agent. The patent supports the company's research on CLIP's protective role in mucosal disorders, with plans to advance the technology through pre-clinical studies.GlobeNewswireVGLS Q4 2014 Shareholder Update LetterVG Life Sciences reported meeting all 2014 goals, including completing Phase I cancer trials and up-listing to OTCQB. The company received $1,022,500 in convertible debentures and has an accumulated deficit of $99.78 million. 2015 goals include starting a Phase I trial with VG1177 and expanding cancer trials.GlobeNewswireNew Data Implicate Components of Adaptive Immunity in Traumatic Brain InjuryDr. Richard Tobin published data showing traumatic brain injury triggers immune-mediated neural damage via CD74-dependent lymphocyte activation. VG Life Sciences' drug VG1177, which targets CD74, improved outcomes in mice, and the company is conducting pre-clinical safety trials.GlobeNewswireVG Life Sciences Inc. Announces Upgrading to OTCQB MarketplaceVG Life Sciences announced it will upgrade from OTC Pink to OTCQB effective October 17, 2014. The company completed prior year audits, filed Form 10, and became a reporting company in August 2014. The upgrade aims to bring financial accountability and transparency.GlobeNewswireVG LIFE SCIENCES, INC. ANNOUNCES SEC FORM 10 REVIEW COMPLETEVG Life Sciences announced the SEC completed its review of its Form 10 filing, submitted June 20, 2014. The company plans to move from the OTC Pink Marketplace to the OTCQB Marketplace. The filing provided comprehensive information on capital structure, financial condition, history, and governance.GlobeNewswireVG Life Sciences Inc. Progress Update Phase I Cancer StudyVG Life Sciences announced completion of enrollment in its phase I study of hydroxychloroquine with sorafenib for advanced solid tumors. The final cohort at maximum doses was deemed safe, allowing planned expansion studies in sarcomas, lung cancer, ovarian cancer, and triple-negative breast cancer.GlobeNewswireVG Life Sciences, Inc. Announces Filing of Form 10 with the SEC.VG Life Sciences filed Form 10 with the SEC on June 19, 2014, providing comprehensive company information. The filing enables annual 10K, quarterly 10Q, and periodic 8K reports, and the company plans to move from OTC Pink to OTCQB for increased liquidity. The company also clarified its loss carry forward of $44 million.GlobeNewswireVG Life Sciences Inc. Moves to Restore Financial Accountability & Completes Prior Year Audits, Plans to File Form 10VG Life Sciences completed prior year audits through December 31, 2013, with KWCO, PC, and plans to file Form 10 with the SEC. The company intends to list on the OTCQB after SEC approval. It is also in preclinical animal safety studies and a Phase I clinical trial.GlobeNewswireVG Life Sciences, Inc.'s Reports on Clinical Outcomes in Phase I Cancer StudyVG Life Sciences reported two clinical responses in its Phase I study of hydroxychloroquine plus sorafenib for advanced solid tumors, including disease stabilization in ovarian and breast cancer patients. The study is expanding to cohort 4 with maximum dosing, with results expected in 60-90 days.GlobeNewswireVG Life Sciences, Inc. Increases Authorized SharesVG Life Sciences increased its authorized common shares to 150,000,000 following a December 31, 2013 shareholder vote. The increase, required by Delaware law, provides shares to cover existing obligations and future capital events. The company, a biotech focused on cancer and infectious disease therapies, holds over 50 patents.